AI news impact · China A-shares
Pharmaron Beijing Co., Ltd. Class A (300759) news impact
On 2026-10-26 Wave Radar's AI rated the news on Pharmaron Beijing Co., Ltd. Class A as neutral (impact score +15%).
An industry report cited Pharmaron's 2026 H1 figures, noting new order growth exceeded 30% and CDMO new orders jumped over 50%, supported by active peptide demand.
- Direction
- Neutral
- Impact score
- +15%
- Confidence
- 75%
- Headlines read
- 1
- Date
- 2026-10-26
AI assessment
Media coverage reiterated strong order growth and CDMO momentum from earlier filings, offering mild positive confirmation though it is not a new corporate disclosure.
Sector impact
Reiterated robust order inflows confirm recovery momentum in CXO demand, providing mild sentiment support to medical outsourcing peers.
Headlines the AI read
- 凯莱英单季净利大涨80%,港股盘中跌逾6%!公司:近年多肽需求旺盛 AkShare/时代周报 · 2026-10-23
Rating history
One rating per trading day the stock was covered.
More on Pharmaron Beijing Co., Ltd. Class A
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.